Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia사우디아라비아의 건강한 성인을 대상으로 백신 접종 16주 후 SARS-CoV-2 감염에 대한 ChAdOx1 백신 1회 접종 후 결과Article Published on 2022-07-012022-09-11 Journal: Annals of Saudi medicine [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission age anti-Nucleocapsid IgG anti-Spike IgG anti-spike IgG level antibody Antibody Response blood sample Blood samples ChAdOx1 ChAdOx1 vaccine Chain Reaction conflict conflict of interest coronavirus cross-sectional study demonstrated detectable dose female had no healthy hospital immunogenicity individual Infection intensive care IQR median Mild occurred outcome participant Participants PCR-confirmed polymerase chain polymerase chain reaction recruited Sample Sample size SARS CoV SARS CoV-2 SARS CoV-2 infection SARS-COV-2 infection Saudi Arabia sensitivity severe acute respiratory syndrome Coronavirus significantly single dose single-center small sample size subject subsequent vaccination [DOI] 10.5144/0256-4947.2022.223 PMC 바로가기 [Article Type] Article
Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine나노입자 전달 TLR4 및 RIG-I 작용제는 SARS-CoV-2 소단위 백신에 대한 면역 반응을 향상시킵니다Article Published on 2022-07-012022-09-11 Journal: Journal of controlled release : official journal o [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] activated Adaptive immune response adjuvant adjuvants agonist Anti-spike anti-Spike IgG Antibody titer Antibody titers Antigen antigen-presenting cell antigen-presenting cells APC APCS B cell B cells BAL Bcl6 Blood bronchoalveolar CD4 CD44 Cell cell population characterized Combination adjuvant COVID-19 COVID-19 protein subunit vaccine CpG DLNs draining lymph node draining lymph nodes Efficacy ENhance follicular Germinal center GL7 helper cell humoral immune responses IgA IgG immune immune response immune responses Immunity IMPROVE in vitro in vivo Increases increases in Infection intramuscular intramuscular vaccination intranasal Intranasal versus intramuscular vaccination intranasally lead lung Lungs lymphocyte memory T memory T cell mice molecular Monophosphoryl lipid A MPLA Native neutralizing antibody titers Pattern recognition pattern recognition receptor Pattern recognition receptors Polymer Population Proinflammatory cytokine Protein subunit protein subunit vaccine Protein subunit vaccines PRR PRRs PUUC reaction receptor receptors responses against retinoic acid retinoic acid-inducible gene I RIG-I robust S1 subunit SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein secretion spike IgA Spike protein stabilized spike protein stimulate subunit Subunit vaccine T cell T cell proliferation the S1 subunit TLR TLR4 TLR7 TLR7/8 TLR9 TLRs Toll-like receptor Toll-like receptors Transmission unique Vaccine vaccine availability vaccine responses variants [DOI] 10.1016/j.jconrel.2022.05.023 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection사전 감염 유무에 관계없이 단일 COVID-19 백신 접종 후 SARS-CoV-2 항체 궤적Article Published on 2022-06-292022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-Spike IgG antibody Antibody Response BNT162b2 ChAdOx1 COVID-19 Infection Survey COVID-19 vaccination dose evaluate Evidence first vaccination General population generate half-live incidence individual infected with SARS-CoV-2 Infection initial median mRNA-1273 population immunity producing receiving responses SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccine significantly single vaccination Single-dose subsequent the median threshold trajectory vaccination Vaccinations Vaccine [DOI] 10.1038/s41467-022-31495-x PMC 바로가기 [Article Type] Article
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구Clinical Trial Published on 2022-06-092022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year [DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses Exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial영국에서 ChAdOx1 nCov-19 또는 BNT162b2 2회 접종 후 3차 추가 접종으로 7가지 COVID-19 백신을 투여한 후 면역원성의 지속성: COV-BOOST 시험의 3개월 분석Clinical Trial Published on 2022-06-012022-09-11 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, [키워드] Ad26 Ad26.COV2.S adenoviral vector adenoviral vector vaccine Analysis anti-Spike IgG antibody AstraZeneca BNT BNT162b2 booster booster dose cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Concentration conducted COV-BOOST COVID-19 COVID-19 vaccine Critical death dose doses evaluate Fractional dose geometric mean geometric mean concentration geometric mean ratio GMR GMRs Heterologous boost highest Homologous boost humoral Humoral response immune response immune responses immunogenicity initial janssen long-lasting maintenance median age mRNA mRNA vaccine mRNA vaccines multicentre naïve no significant difference Oxford-AstraZeneca participant persistence Pfizer-BioNTech Phase 2 phase 2 trial randomised referred to response responses SARS-CoV-2 Seven severe disease significant difference significantly higher the vaccine third dose Transmission Trial Vaccine Vaccines variants of concern while [DOI] 10.1016/j.jinf.2022.04.018 PMC 바로가기 [Article Type] Clinical Trial
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects다발성 경화증 환자에서 SARS-CoV-2 체액 반응의 장기간 지속Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age anti-Spike IgG anti-spike IgG levels appearance benefit BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2-mRNA vaccine booster booster vaccination booster vaccinations Cladribine Cohort comparable coronavirus Coronavirus-19 dimethyl fumarate Disease modifying therapies dose eight evaluated faster fingolimod Fingolimod- Glatiramer Glatiramer acetate groups healthy control healthy controls humoral humoral immune response Humoral persistence Humoral response IgG IgG levels interferon long term mRNA vaccine Multiple multiple sclerosis Natalizumab Ocrelizumab pandemic Patient patients persistence receiving regimen respiratory SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike protein severe acute respiratory syndrome Coronavirus spike Spike protein subject subjects Teriflunomide the SARS-CoV-2 titre variants [DOI] 10.1016/j.msard.2022.103800 PMC 바로가기 [Article Type] Article
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases리툭시맙은 자가면역 질환에서 COVID-19 백신에 대한 B 세포 반응을 손상시키지만 T 세포 반응을 손상시키지 않습니다Article Published on 2022-06-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence activated anti-spike antibody response anti-Spike IgG Antibody Response Autoimmune disease autoimmune disease patient BNT162b2 CD4 CD8 CD8 T cell cellular response control group COVID-19 COVID-19 vaccine cytokine dose flow cytometry functional healthy control healthy controls humoral Immunosuppressant immunosuppressants interferon-γ Messenger RNA mRNA Necrosis Neutralization assay neutralizing antibody not different Patient patients patients treated performed Pfizer-BioNTech proportion Responder response rituximab RTX SARS-CoV-2 peptide SARS-CoV-2 spike peptide shown staining T cell response the healthy the vaccine time treated vaccine dose [DOI] 10.1002/art.42058 PMC 바로가기 [Article Type] Article
Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers의료 종사자의 두 번째 BNT162b2 COVID-19 예방 접종 후 항-스파이크 IgG 항체 수준의 역학Article Published on 2022-06-012022-09-12 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition Adverse reaction age alcohol allergies allergy anti-Spike IgG Anti-spike IgG antibody anti-spike IgG level anti-spike IgG levels Antibody titer association BMI BNT162b2 categories correlation country COVID-19 COVID-19 vaccination COVID-19 vaccines cross-sectional dose Dynamics evaluate Fever geometric mean titer Health care worker IgG IgG antibody Japanese observation Older Older age participant remained second vaccination Sex Side effect significantly significantly lower smoking statistically significant vaccination vaccine dose Vaccine-induced immunity was performed were assessed [DOI] 10.1016/j.jiac.2022.02.024 PMC 바로가기 [Article Type] Article
IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes뚜렷한 계절성 코로나바이러스-보존 SARS-CoV-2 스파이크 하위 도메인을 표적으로 하는 IgG는 차별적인 COVID-19 질병 결과와 상관관계가 있습니다Article Published on 2022-05-312022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] Activation ADE amplification anti-Spike IgG anti-spike IgG levels anti-spike IgG response Anti-spike IgG responses antibody antibody-mediated effector responses Betacoronavirus betacoronaviruses caused conserved convalescent individual coronavirus COVID-19 COVID-19 disease COVID-19 patient COVID-19 severity CoVs CP: Immunology CP: Microbiology cross-reactivity Deleterious disease disease severity Early detection epitope Epitopes Fc-gamma receptor activation FcγR fusion protein fusion protein region greater heptad repeat heptad repeat region human betacoronavirus human betacoronavirus. humoral IgG IgG responses immunodominant epitope immunology lowest memory response Microbiology observé OC43 offer outcome predict profile Protective recall receptor responses SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS1 seasonal coronaviruses severe COVID-19 patient severe COVID-19 patients severe disease significantly Spectrum Spike protein the SARS-CoV-2 virus β-CoVs [DOI] 10.1016/j.celrep.2022.110904 PMC 바로가기 [Article Type] Article